Literature DB >> 16960008

An antigen produced by splicing of noncontiguous peptides in the reverse order.

Edus H Warren1, Nathalie J Vigneron, Marc A Gavin, Pierre G Coulie, Vincent Stroobant, Alexandre Dalet, Scott S Tykodi, Suzanne M Xuereb, Jeffrey K Mito, Stanley R Riddell, Benoît J Van den Eynde.   

Abstract

CD8-positive T lymphocytes recognize peptides that are usually derived from the degradation of cellular proteins and are presented by class I molecules of the major histocompatibility complex. Here we describe a human minor histocompatibility antigen created by a polymorphism in the SP110 nuclear phosphoprotein gene. The antigenic peptide comprises two noncontiguous SP110 peptide segments spliced together in reverse order to that in which they occur in the predicted SP110 protein. The antigenic peptide could be produced in vitro by incubation of precursor peptides with highly purified 20S proteasomes. Cutting and splicing probably occur within the proteasome by transpeptidation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16960008     DOI: 10.1126/science.1130660

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  82 in total

Review 1.  Database of T cell-defined human tumor antigens: the 2013 update.

Authors:  Nathalie Vigneron; Vincent Stroobant; Benoît J Van den Eynde; Pierre van der Bruggen
Journal:  Cancer Immun       Date:  2013-07-15

2.  Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules.

Authors:  Celia R Berkers; Annemieke de Jong; Karianne G Schuurman; Carsten Linnemann; Hugo D Meiring; Lennert Janssen; Jacques J Neefjes; Ton N M Schumacher; Boris Rodenko; Huib Ovaa
Journal:  J Immunol       Date:  2015-09-23       Impact factor: 5.422

3.  Peptide Splicing in the Proteasome Creates a Novel Type of Antigen with an Isopeptide Linkage.

Authors:  Celia R Berkers; Annemieke de Jong; Karianne G Schuurman; Carsten Linnemann; Jan A J Geenevasen; Ton N M Schumacher; Boris Rodenko; Huib Ovaa
Journal:  J Immunol       Date:  2015-09-23       Impact factor: 5.422

4.  Computational prediction of cleavage using proteasomal in vitro digestion and MHC I ligand data.

Authors:  Yu-feng Lu; Hao Sheng; Yi Zhang; Zhi-yang Li
Journal:  J Zhejiang Univ Sci B       Date:  2013-09       Impact factor: 3.066

Review 5.  A peptide's perspective on antigen presentation to the immune system.

Authors:  Jacques Neefjes; Huib Ovaa
Journal:  Nat Chem Biol       Date:  2013-12       Impact factor: 15.040

6.  Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion.

Authors:  Thomas Delong; Timothy A Wiles; Rocky L Baker; Brenda Bradley; Gene Barbour; Richard Reisdorph; Michael Armstrong; Roger L Powell; Nichole Reisdorph; Nitesh Kumar; Colleen M Elso; Megan DeNicola; Rita Bottino; Alvin C Powers; David M Harlan; Sally C Kent; Stuart I Mannering; Kathryn Haskins
Journal:  Science       Date:  2016-02-12       Impact factor: 47.728

Review 7.  Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.

Authors:  Gabor Mester; Vanessa Hoffmann; Stefan Stevanović
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

8.  Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.

Authors:  Delia F Tifrea; Sukumar Pal; Jean-Luc Popot; Melanie J Cocco; Luis M de la Maza
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

Review 9.  Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.

Authors:  Xin Feng; Kwok Min Hui; Hashem M Younes; Anthony G Brickner
Journal:  Trends Immunol       Date:  2008-10-25       Impact factor: 16.687

10.  Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein.

Authors:  Guifeng Sun; Sukumar Pal; Joseph Weiland; Ellena M Peterson; Luis M de la Maza
Journal:  Vaccine       Date:  2009-05-27       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.